3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Head & Neck
5
Gynecologic
4
Thoracic
3
Genitourinary
3
Gastrointestinal
3
Dermatologic
3
Sarcoma
1
Lymphoid
1
Conditions
Mycosis Fungoides
3
Recurrence
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lymphoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Natural Killer/T-cell Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Myeloid, Acute
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Glioma
1
Glioblastoma
1
Carcinoma in Situ
1
Interventions
pembrolizumab
4
Paclitaxel
2
vocimagene amiretrorepvec
1
stenoparib
1
olaparib
1
mirabegron
1
epacadostat
1
durvalumab
1
ciforadenant
1
cemiplimab
1
atezolizumab
1
advexin
1
Temozolomide
1
Rituximab
1
Pharmacogenomic Variants
1
Nivolumab
1
LTX-315
1
Ipilimumab
1
IACS-010759
1
HMPL-013
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Flucytosine
1
Carboplatin
1
Capecitabine
1
CPI-006
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Antibodies
1
AZD5153
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
cemiplimab
×
Lymphoid
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled